-
公开(公告)号：US06676975B2
公开(公告)日：2004-01-13
申请号：US10074039
申请日：2002-02-14
IPC分类号： A61K3578
CPC分类号： A61K36/804 , A61K36/00 , A61K36/185 , A61K36/238 , A61K36/48 , A61K36/484 , A61K36/538 , A61K36/65 , A61K36/716 , A61K36/73 , A61K36/75 , A61K36/899 , Y10S514/861 , Y10S514/863 , Y10S514/885 , Y10S514/886 , Y10S514/887 , A61K2300/00
摘要： This application relates to a material which is suitable for the treatment of atopic disease, non-atopic eczema or psoriasis. The material can be extracted from a freeze-dried decoction of a mixture comprising the following Chinese herbs: Radix Ledebouriella, Fructus Tribuli, Herba Potentilla chinensis, Caulis Clematis armandii, Radix Rehmannia, Radix Glycyrrhiza, Radix Paeonia rubra, Cortex Dictamni radicis, Herba Lopatheri, Spica Schizonepetae. The material comprises one or more of those components present in the freeze-dried decoction which run with Rf values in the ranges 0.00 to 0.100, 0.167 to 0.300, 0.400 to 0.533, 0.700 to 0.833 or 0.900 to 0.967 if the freeze-dried decoction is diluted in aqueous solution and subjected to chromatography on a Whatman 2 cms×55 cms×3 mm cellulose strip for 10 hours using a solvent mixture of butanol, ethanol and water in the proportions 4:1:1.
摘要翻译： 本申请涉及适用于治疗特应性疾病，非特应性湿疹或牛皮癣的材料。 该材料可以从包含以下中草药的混合物的冷冻干燥汤中提取：枸杞，枸杞，中华Her草，铁线莲，地黄，甘草，芍药，茯苓，草本茯苓 ，Spica Schizonepetae。 该物质包含存在于冷冻干燥煎煮中的一种或多种组分，如果冷冻干燥的煎煮是在冰冷干燥汤中，则以Rf值为范围为0.00至0.100,0.167至0.300,0.400至0.533,0.700至0.833或0.900至0.967 在水溶液中稀释，并在Whatman 2 cmsx55 cmsx3 mm纤维素条上进行色谱分离，使用丁醇，乙醇和水的溶剂混合物，比例为4:1:1。
-
公开(公告)号：US06399112B1
公开(公告)日：2002-06-04
申请号：US08750848
申请日：1996-12-24
IPC分类号： A61K3578
CPC分类号： A61K36/804 , A61K36/00 , A61K36/185 , A61K36/238 , A61K36/48 , A61K36/484 , A61K36/538 , A61K36/65 , A61K36/716 , A61K36/73 , A61K36/75 , A61K36/899 , Y10S514/861 , Y10S514/863 , Y10S514/885 , Y10S514/886 , Y10S514/887 , A61K2300/00
摘要： This application relates to a material which is suitable for the treatment of atopic disease, non-atopic eczema or psoriasis. The material can be extracted from a freeze-dried decoction of a mixture comprising the following Chinese herbs: Radix Ledebouriella, Fructus Tribuli, Herba Potentilla chinensis, Caulis Clematis armandii, Radix Rehmannia, Radix Glycyrrhiza, Radix Paeonia rubra, Cortex Dictamni radicis, Herba Lopatheri, Spica Schizonepetae. The material comprises one or more of those components present in the freeze-dried decoction which run with Rf values in the ranges 0.00 to 0.100, 0.167 to 0.300, 0.400 to 0.533, 0.700 to 0.833 or 0.900 to 0.967 if the freeze-dried decoction is diluted in aqueous solution and subjected to chromatography on a Whatman 2 cms×55 cms×3 mm cellulose strip for 10 hours using a solvent mixture of butanol, ethanol and water in the proportions 4:1:1.
摘要翻译： 本申请涉及适用于治疗特应性疾病，非特应性湿疹或牛皮癣的材料。 该材料可以从包含以下中草药的混合物的冷冻干燥汤中提取：枸杞，枸杞，中华Her草，铁线莲，地黄，甘草，芍药，茯苓，草本茯苓 ，Spica Schizonepetae。 该物质包含存在于冷冻干燥煎煮中的一种或多种组分，如果冷冻干燥的煎煮是在冰冷干燥汤中，则以Rf值为范围为0.00至0.100,0.167至0.300,0.400至0.533,0.700至0.833或0.900至0.967 在水溶液中稀释，并在Whatman 2 cmsx55 cmsx3 mm纤维素条上进行色谱分离，使用丁醇，乙醇和水的溶剂混合物，比例为4:1:1。
-
公开(公告)号：US07341746B2
公开(公告)日：2008-03-11
申请号：US10716506
申请日：2003-11-20
IPC分类号： A61K36/00
CPC分类号： A61K36/804 , A61K36/00 , A61K36/185 , A61K36/238 , A61K36/48 , A61K36/484 , A61K36/538 , A61K36/65 , A61K36/716 , A61K36/73 , A61K36/75 , A61K36/899 , Y10S514/861 , Y10S514/863 , Y10S514/885 , Y10S514/886 , Y10S514/887 , A61K2300/00
摘要： This application relates to a material which is suitable for the treatment of atopic disease, non-atopic eczema or psoriasis. The material can be extracted from a freeze-dried decoction of a mixture comprising the following Chinese herbs: Radix Ledebouriella, Fructus Tribuli, Herba Potentilla chinensis, Caulis Clematis armandii, Radix Rehmannia, Radix Glycyrrhiza, Radix Paeonia rubra, Cortex Dictamni radicis, Herba Lopatheri, Spica Schizonepetae. The material comprises one or more of those components present in the freeze-dried decoction which run with Rf values in the ranges 0.00 to 0.100, 0.167 to 0.300, 0.400 to 0.533, 0.700 to 0.833 or 0.900 to 0.967 if the freeze-dried decoction is diluted in aqueous solution and subjected to chromatography on a Whatman 2 cms×55 cms×3 mm cellulose strip for 10 hours using a solvent mixture of butanol, ethanol and water in the proportions 4:1:1.
摘要翻译： 本申请涉及适用于治疗特应性疾病，非特应性湿疹或牛皮癣的材料。 该材料可以从包含以下中草药的混合物的冷冻干燥汤中提取：枸杞，枸杞，中华Her草，铁线莲，地黄，甘草，芍药，茯苓，草本茯苓 ，Spica Schizonepetae。 该物质包含存在于冷冻干燥煎煮中的一种或多种组分，如果冷冻干燥的煎煮是在冰冷干燥汤中，则以Rf值为范围为0.00至0.100,0.167至0.300,0.400至0.533,0.700至0.833或0.900至0.967 在水溶液中稀释，并在Whatman 2 cmsx55 cmsx3 mm纤维素条上进行色谱分离，使用丁醇，乙醇和水的溶剂混合物，比例为4:1:1。
-
公开(公告)号：US20130245109A9
公开(公告)日：2013-09-19
申请号：US13486227
申请日：2012-06-01
IPC分类号： A61K9/00
CPC分类号： B65D65/38 , A61K9/006 , A61K31/05 , A61K31/352 , A61K36/185 , B65B31/00
摘要： The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
-
公开(公告)号：US20100092617A1
公开(公告)日：2010-04-15
申请号：US12519688
申请日：2007-12-17
IPC分类号： A23L1/0522 , C09K3/00 , C11B5/00 , A23L1/302 , A23L1/303 , A23L1/304 , A23L1/10 , A21D13/08 , A23L1/16 , A23L1/29 , B65D85/72
CPC分类号： A23D9/013 , A21D2/165 , A21D2/32 , A21D2/362 , A23D7/003 , A23D7/0053 , A23D7/011 , A23D9/007 , A23L2/02 , A23L2/52 , A23L19/09 , A23L29/10 , A23L33/12 , A23L33/15 , A23L33/16 , A23V2002/00 , A23V2250/1882 , A23V2250/187 , A23V2250/1868 , A23V2250/2042 , A23V2250/202 , A23V2250/1842 , A23V2250/702 , A23V2250/71 , A23V2250/712
摘要： The invention concerns compositions containing polyunsaturated fatty acids (PUFA's). More particularly it concerns a composition containing PUFA's, (particularly long chain PUFAs derived from marine sources, particularly fish, and its use in fortifying consumables, such as food, drink, supplements and nutraceutical or pharmaceutical products. More particularly it is a substantially non aqueous additive mix, for introducing poly unsaturated fatty acids into ingestible products, which when hydrated forms an oil in water emulsion, comprising one or more poly unsaturated fatty acids or a source thereof and one or more emulsifying agents. The mix can be added to, particularly farinaceous products, to provide PUFA supplementation.
摘要翻译： 本发明涉及含有多不饱和脂肪酸（PUFA's）的组合物。 更具体地说，它涉及含有PUFA的组合物（特别是源自海洋来源的长链PUFA，特别是鱼类，以及其在强化消耗品中的用途，例如食品，饮料，补充剂和营养药品或药物产品，更特别地，它是基本上非水性的 添加剂混合物，用于将多不饱和脂肪酸引入可摄入产品中，当其水合时形成水包油乳液，其包含一种或多种多不饱和脂肪酸或其来源和一种或多种乳化剂，所述混合物可特别加入 产品，提供PUFA补充。
-
公开(公告)号：US06350478B1
公开(公告)日：2002-02-26
申请号：US08826419
申请日：1997-03-27
IPC分类号： A61K3578
CPC分类号： A61K36/282 , A61K2300/00
摘要： Extracts of herbs of the Artemisia family, some of which have been known in traditional medicine to have anti-diabetic effects, are fractionated chromatographically to remove unacceptable mutagenetic properties while retaining effectiveness against Diabetes mellitus. Certain fractions are found to be insulinomemetic while others have glucagon antagonistic properties. Mixtures of such fractions have optimum clinical effect.
摘要翻译： 艾滋病家族的草药提取物，其中一些在传统医学中已知具有抗糖尿病作用，经色谱分级分离，以消除不可接受的诱变特性，同时保留对糖尿病的有效性。 发现某些级分是胰岛素抑制剂，而另一些则具有胰高血糖素拮抗性质。 这些级分的混合物具有最佳的临床效果。
-
公开(公告)号：US08211946B2
公开(公告)日：2012-07-03
申请号：US12704729
申请日：2010-02-12
CPC分类号： B65D65/38 , A61K9/006 , A61K31/05 , A61K31/352 , A61K36/185 , B65B31/00
摘要： The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
摘要翻译： 本发明涉及药物制剂，更具体地涉及含有通过泵作用喷雾给药的大麻素的制剂。 特别地，本发明涉及用于通过粘膜表面施用亲脂性药物的药物制剂，其包含：至少一种亲脂性药物，溶剂和共溶剂，其中存在于溶剂和共溶剂中的溶剂和共溶剂的总量 制剂大于制剂的55重量％/重量，并且制剂不含自乳化剂和/或氟化推进剂。
-
公开(公告)号：US07088914B2
公开(公告)日：2006-08-08
申请号：US10494136
申请日：2002-10-31
申请人： Brian Anthony Whittle , John Erwin Richard Bowyer , Anthony Hamish Harper , Anthony Vanhinsberg , Christopher Robert Melbourne , David Downs , Rajiv Bobby Dave
发明人： Brian Anthony Whittle , John Erwin Richard Bowyer , Anthony Hamish Harper , Anthony Vanhinsberg , Christopher Robert Melbourne , David Downs , Rajiv Bobby Dave
CPC分类号： A61K9/007 , A61M11/002 , A61M11/041 , A61M15/0045
摘要： A device for vaporizing a medicament (4). The device comprises a resistive element (9) on which the medicament is deposited. The device also comprises a source of electrical power which can be connected across the resistive element to vaporize the medicament. The element is configured to provide a central cool region (11) on which the medicament is deposited and a relatively hotter region (12) surrounding the cool region. Through holes (13) are also provided. The resistive element may be a mesh, foil or a tile on which a resistive pattern is deposited.
摘要翻译： 一种用于蒸发药物（4）的装置。 该装置包括其上沉积有药物的电阻元件（9）。 该装置还包括电源，其可以跨越电阻元件连接以蒸发药物。 该元件构造成提供其上沉积有药物的中央冷却区域（11）和围绕该冷区域的相对较热的区域（12）。 还提供通孔（13）。 电阻元件可以是其上沉积有电阻图案的网状物，箔或瓷砖。
-
公开(公告)号：US20130109747A1
公开(公告)日：2013-05-02
申请号：US13486227
申请日：2012-06-01
IPC分类号： A61K9/00
CPC分类号： B65D65/38 , A61K9/006 , A61K31/05 , A61K31/352 , A61K36/185 , B65B31/00
摘要： The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
摘要翻译： 本发明涉及药物制剂，更具体地涉及含有通过泵作用喷雾给药的大麻素的制剂。 特别地，本发明涉及用于通过粘膜表面施用亲脂性药物的药物制剂，其包含：至少一种亲脂性药物，溶剂和共溶剂，其中存在于溶剂和共溶剂中的溶剂和共溶剂的总量 制剂大于制剂的55重量％/重量，并且制剂不含自乳化剂和/或氟化推进剂。
-
10.发明申请NEW PHARMACEUTICAL FORMULATION COMPRISING CANNABIDIOL AND TETRAHYDROCANNABIDIVARIN 审中-公开包含CANNABIDOL和四氢胞嘧啶的新药物制剂公开(公告)号：US20100317729A1
公开(公告)日：2010-12-16
申请号：US12667555
申请日：2008-07-04
IPC分类号： A61K31/352 , A61K31/05 , A61P3/04 , A61P25/18 , A61P19/10 , A61P25/32 , A61P25/34 , A61P25/30 , A61P29/00
CPC分类号： A61K36/185 , A61K31/05 , A61K31/352 , A61K2300/00
摘要： The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably both the inverse agonist of the CB1 and/or CB2 receptor and the neutral antagonist of the CB1 and/or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).
摘要翻译： 本发明涉及一种新的药物制剂，其包含：（i）一种或多种作为CB1和/或CB2受体的反向激动剂的化合物的混合物; 和（ii）一种或多种作为CB1和/或CB2受体的中性拮抗剂的化合物。 CB1和/或CB2受体的反向激动剂和CB1和/或CB2受体的中性拮抗剂优选是大麻素。 优选地，大麻素是四氢大麻脂质（THCV）和大麻二酚（CBD）。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.025 秒)
